MiMedx

3X recent stem cell & regenerative medicine good news

Stem cells spina bifida

In the past month or two there has been a steady stream of good news in the stem cell and regenerative medicine world. Here are three examples. Fate Therapeutics announced the first US IND for an induced pluripotent stem cell (IPSC)-related product. Its cleared product, FT500, is an off-the-shelf natural killer-based cancer immunotherapy. I expect …

3X recent stem cell & regenerative medicine good news Read More »

Stem cell news July 2018: RMATs, RTT, MiMedx mess, clinic family ties & more

Bob-Comella-U.S.-Stem-

The year of 2018 has already been a wild one for stem cell news. There are many developments on a variety of fronts. Here are some of the most notable news bites of the last month or so. RMAT Wave. The FDA continues its warp-speed issuance of Regenerative Medicine Advanced Therapy (RMAT) designations with 20 …

Stem cell news July 2018: RMATs, RTT, MiMedx mess, clinic family ties & more Read More »

Tom Price & MiMedx: a stem cell connection?

Tom-Price-HHS-Senate

What’s the deal with Trump’s HHS Secretary pick Rep. Tom Price (now testifying before the Senate) and the amniotic tissue/stem cell company MiMedx that’s caused some buzz in the last 48 hours? I’ve been following MiMedx for a few years since it received an untitled letter from the FDA and I noted its claim of one its …

Tom Price & MiMedx: a stem cell connection? Read More »

REGROW Act, Mark Kirk Lobbying & Contributions Yield Stem Cell Surprises

Center-for-Responsive-Politics

The money behind a piece of legislation can provide unique insights into the back story and this is definitely true for the REGROW Act that would reduce FDA oversight of the investigational use of stem cells in patients. Senator Mark Kirk of Illinois, who is facing probable defeat next week in his reelection bid according to …

REGROW Act, Mark Kirk Lobbying & Contributions Yield Stem Cell Surprises Read More »

MiMedx (MDXG) placental “stem cell magnet” drugs attract FDA attention and lawsuit

ABC News just reported that the FDA is allgedly “cracking down” on the publicly traded company, MiMedx (MDXG), which sells a placental derivative touted for healing powers. The Wall Street Journal is also following the story. According to ABC News: MiMedx is a publically traded, for-profit company that takes donated human placentas — solicited via a website featuring …

MiMedx (MDXG) placental “stem cell magnet” drugs attract FDA attention and lawsuit Read More »